General
Preferred name
FELBAMATE
Synonyms
Felbamate (hydrate) ()
W-554 (hydrate) ()
ADD-03055 (hydrate) ()
W-554 ()
ADD-03055 ()
Felbatol, ADD-03055,W-554 ()
Felbamate hydrate ()
NSC-759866 ()
Felbamato ()
Felbatol ()
Taloxa ()
Felbamate-d4 ()
P&D ID
PD002715
CAS
25451-15-4
1177501-39-1
106817-52-1
Tags
available
drug
Approved by
FDA
First approval
1993
Drug indication
Epilepsy
Drug Status
approved
withdrawn
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Felbamate is an anticonvulsant. (GtoPdb)
DESCRIPTION Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
PRICE 29
DESCRIPTION Kir6 (KATP) channel opener (Tocris Bioactive Compound Library)
DESCRIPTION NMDA antagonist, acts glycine site (Tocriscreen Plus)
DESCRIPTION Anticonvulsant; glutamate receptor antagonist (LOPAC library)
DESCRIPTION NMDA antagonist, acts glycine site (Tocriscreen Total)
DESCRIPTION Felbamate is an inhibitor of NMDA receptors and a modulator of GABAA receptors that also has broad-spectrum inhibitory activity against excitatory amino acid receptors. Felbamate is an anticonvulsant used to treat severe epilepsy. (Enamine Bioactive Compounds)
DESCRIPTION Felbamate (W-554) is an Anti-epileptic Agent. The physiologic effect of felbamate is by means of Decreased Central Nervous System Disorganized Electrical Activity. (TargetMol Bioactive Compound Library)
DESCRIPTION The hydrate of Felbamate which is an effective anticonvulsant agent. It was found to be clinically active for probably restraining the effectivity of NMDA. (BOC Sciences Bioactive Compounds)
Compound Sets
34
AdooQ Bioactive Compound Library
A11862
BOC Sciences Bioactive Compounds
felbamate-hydrate-cas-1177501-39-1-item-474371
Cayman Chemical Bioactives
18000
28489
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1094
ChEMBL Drugs
CHEMBL1094
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00949
DrugBank Approved Drugs
DB00949
DrugCentral
1140
DrugCentral Approved Drugs
1140
DrugMAP
DM1V5ZS
DrugMAP Approved Drugs
DM1V5ZS
DrugMatrix
Enamine Bioactive Compounds
EBC-06581
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS100010
Guide to Pharmacology
5473
LOPAC library
Mcule NIBR MoA Box Subset
MCULE-2661497722
MedChem Express Bioactive Compound Library
HY-B0184
NCATS Inxight Approved Drugs
X72RBB02N8
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Felbamate
TargetMol Bioactive Compound Library
T1946
Tocris Bioactive Compound Library
0869
Tocriscreen Plus
0869
Tocriscreen Total
Withdrawn 2.0
w217
External IDs
51
Properties
(calculated by RDKit )
Molecular Weight
238.1
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
1
Aromatic Ring Count
1
cLogP
0.96
TPSA
104.64
Fraction CSP3
0.27
Chiral centers
0.0
Largest ring
6.0
QED
0.8
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Ion Channels
Target
iGluR
Glutamate [NMDA] receptor
GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B
NMDAR
NMDA Receptor
Pathway
Membrane Transporter/Ion Channel
Neuronal Signaling
Neuroscience
MOA
Unknown molecular target
Antagonist
GABA(A) Receptor Modulators
glutamate receptor antagonist
Primary Target
NMDA Receptors
Member status
virtual
Indication
epilepsy
ATC
N03AX10
Toxicity type
neurological
Therapeutic Class
Antiepileptic Agents
Solubility
10 mM in DMSO
Source data